416 related articles for article (PubMed ID: 22419375)
1. Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents.
Miao Y; Yu-Jie Z; Zhi-Jian W; Dong-Mei S; Yu-Yang L; Ying-Xin Z; Fei G; Shi-Wei Y; De-An J
Catheter Cardiovasc Interv; 2012 Sep; 80(3):361-7. PubMed ID: 22419375
[TBL] [Abstract][Full Text] [Related]
2. Impact of chronic kidney disease on long-term clinical outcomes after percutaneous coronary intervention with drug-eluting or bare-metal stents.
Kersting S; Grumann T; Hummel J; Hauschke D; Bode C; Hehrlein C
Crit Pathw Cardiol; 2012 Sep; 11(3):152-9. PubMed ID: 22825536
[TBL] [Abstract][Full Text] [Related]
3. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
Tada T; Byrne RA; Simunovic I; King LA; Cassese S; Joner M; Fusaro M; Schneider S; Schulz S; Ibrahim T; Ott I; Massberg S; Laugwitz KL; Kastrati A
JACC Cardiovasc Interv; 2013 Dec; 6(12):1267-74. PubMed ID: 24355117
[TBL] [Abstract][Full Text] [Related]
4. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.
Jones DA; Rathod KS; Gallagher S; Weerackody R; Knight CJ; Rothman MT; Mathur A; Jain AK; Timmis AD; Wragg A
Catheter Cardiovasc Interv; 2013 May; 81(6):E237-44. PubMed ID: 22707383
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
[TBL] [Abstract][Full Text] [Related]
6. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
Han YL; Zhang L; Yang LX; Liu HL; Qu P; Li WM; Jiang TM; Li SM; Jing QM; Zhang QY; Xu B; Li Y; Gao RL
EuroIntervention; 2012 Nov; 8(7):815-22. PubMed ID: 23171802
[TBL] [Abstract][Full Text] [Related]
7. One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent.
Barthelemy O; Helft G; Silvain J; Bellemain-Appaix A; Beygui F; Choussat R; Berman E; Collet JP; Montalescot G; Metzger JP; Le Feuvre C
Arch Cardiovasc Dis; 2011 Dec; 104(12):604-10. PubMed ID: 22152512
[TBL] [Abstract][Full Text] [Related]
8. Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention.
Parikh PB; Jeremias A; Naidu SS; Brener SJ; Lima F; Shlofmitz RA; Pappas T; Marzo KP; Gruberg L
Catheter Cardiovasc Interv; 2012 Sep; 80(3):352-7. PubMed ID: 22566286
[TBL] [Abstract][Full Text] [Related]
9. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials.
Baber U; Giustino G; Sartori S; Aquino M; Stefanini GG; Steg PG; Windecker S; Leon MB; Wijns W; Serruys PW; Valgimigli M; Stone GW; Dangas GD; Morice MC; Camenzind E; Weisz G; Smits PC; Kandzari D; Von Birgelen C; Mastoris I; Galatius S; Jeger RV; Kimura T; Mikhail GW; Itchhaporia D; Mehta L; Ortega R; Kim HS; Kastrati A; Chieffo A; Mehran R
JACC Cardiovasc Interv; 2016 Jan; 9(1):28-38. PubMed ID: 26762908
[TBL] [Abstract][Full Text] [Related]
10. Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial.
Crimi G; Leonardi S; Costa F; Adamo M; Ariotti S; Valgimigli M
Int J Cardiol; 2016 Jun; 212():110-7. PubMed ID: 27038714
[TBL] [Abstract][Full Text] [Related]
11. Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
Cassese S; De Luca G; Villari B; Berti S; Bellone P; Alfieri A; Montinaro A; Quaranta G; Marraccini P; Piscione F;
Catheter Cardiovasc Interv; 2012 Sep; 80(3):408-16. PubMed ID: 21735531
[TBL] [Abstract][Full Text] [Related]
12. Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting.
Iqbal J; Sumaya W; Tatman V; Parviz Y; Morton AC; Grech ED; Campbell S; Storey RF; Gunn J
EuroIntervention; 2013 May; 9(1):62-9. PubMed ID: 23685296
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in patients with renal impairment undergoing percutaneous coronary intervention and implantation of the Endeavor zotarolimus-eluting stent: 1- and 2-year data from the E-Five Registry.
Rothman MT; Jain AK;
Catheter Cardiovasc Interv; 2012 Nov; 80(6):885-92. PubMed ID: 22517785
[TBL] [Abstract][Full Text] [Related]
14. Short and long term outcome of percutaneous coronary intervention with drug eluting stent and bare metal stent in patients with chronic kidney disease.
Resmini C; Di Cuia M; Ballocca F; D'Ascenzo F; Bollati M; Moretti C; Omedè PL; Sciuto F; Gaita F; Sheiban I
Minerva Cardioangiol; 2012 Dec; 60(6):573-80. PubMed ID: 23147435
[TBL] [Abstract][Full Text] [Related]
15. Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era: Pooled Analysis of the Korean Multicenter Drug-Eluting Stent Registry.
Lee JM; Kang J; Lee E; Hwang D; Rhee TM; Park J; Kim HL; Lee SE; Han JK; Yang HM; Park KW; Na SH; Kang HJ; Koo BK; Kim HS
JACC Cardiovasc Interv; 2016 Oct; 9(20):2097-2109. PubMed ID: 27692820
[TBL] [Abstract][Full Text] [Related]
16. Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis).
Waksman R; Kirtane AJ; Torguson R; Cohen DJ; Ryan T; Räber L; Applegate R; Waxman S; Gordon P; Kaneshige K; Leon MB;
JACC Cardiovasc Interv; 2014 Oct; 7(10):1093-102. PubMed ID: 25240540
[TBL] [Abstract][Full Text] [Related]
17. Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents.
Sai E; Shimada K; Miyauchi K; Masaki Y; Kojima T; Miyazaki T; Kurata T; Ogita M; Tsuboi S; Yoshihara T; Miyazaki T; Ohsaka A; Daida H
Heart Vessels; 2016 May; 31(5):694-701. PubMed ID: 25863806
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease: A Patient-Level Pooled Analysis of 6,081 Patients.
Piccolo R; Pilgrim T; Heg D; Franzone A; Rat-Wirtzler J; Räber L; Silber S; Serruys PW; Jüni P; Windecker S
JACC Cardiovasc Interv; 2015 Nov; 8(13):1657-66. PubMed ID: 26585615
[TBL] [Abstract][Full Text] [Related]
19. Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.
Siddiqi OK; Smoot KJ; Dufour AB; Cho K; Young M; Gagnon DR; Ly S; Temiyasathit S; Faxon DP; Gaziano JM; Kinlay S
Heart; 2015 Oct; 101(19):1569-76. PubMed ID: 26209334
[TBL] [Abstract][Full Text] [Related]
20. Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies.
Zimarino M; Corazzini A; Ricci F; Di Nicola M; De Caterina R
JACC Cardiovasc Interv; 2013 Jul; 6(7):687-95. PubMed ID: 23769650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
